Welcome to our dedicated page for Tela Bio SEC filings (Ticker: TELA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how TELA Bio turns its OviTex soft-tissue matrix into revenue means wading through pages of FDA trial updates, surgeon adoption metrics, and reimbursement disclosures. Investors hunting for device approval timelines or shifts in R&D spend often find the raw SEC text overwhelming.
With “TELA Bio SEC filings explained simply”, Stock Titan’s AI-powered hub solves that. It reads every “TELA Bio quarterly earnings report 10-Q filing” moments after it hits EDGAR and delivers a plain-English summary of margins, unit volumes, and hospital penetration. Need to see whether executives are buying shares? The platform flags “TELA Bio Form 4 insider transactions real-time” alongside a digest that puts each trade in context. You can jump from an “TELA Bio 8-K material events explained” alert—often new clinical data—to a side-by-side trend chart without opening a PDF.
Below, you’ll find every document type:
- 10-K: Our “TELA Bio annual report 10-K simplified” narrative highlights pipeline milestones, manufacturing capacity, and competitive devices.
- 10-Q: Rapid “TELA Bio earnings report filing analysis” surfaces quarter-over-quarter sales to hospitals and cash burn.
- Form 4: Track “TELA Bio insider trading Form 4 transactions” and “TELA Bio executive stock transactions Form 4” to monitor leadership confidence before catalysts.
- DEF 14A: The “TELA Bio proxy statement executive compensation” breakdown shows how pay aligns with clinical adoption goals.
Whether you’re “understanding TELA Bio SEC documents with AI” for the first time or refining a detailed DCF model, our real-time feeds, concise AI annotations, and expert context turn dense regulatory text into clear insight—so you can focus on evaluating surgical innovation, not searching for it.
PCRX Q2-25 topline inched ahead but margins deteriorated. Net product sales rose 2.2 % YoY to $180.3 m; EXPAREL still dominates (79 % of sales). Total revenue reached $181.1 m (+1.7 %). Cost discipline at the plant level cut COGS 7.7 %, lifting gross margin to 77 % (vs 75 %), but a 39 % jump in R&D and 30 % jump in SG&A swung operating profit down 70 % to $8.5 m. After higher other charges, the quarter printed a $4.8 m loss (-$0.11/sh) versus $18.9 m profit last year.
Balance sheet stable. Cash & equivalents improved to $300.5 m; total liquidity (cash+short-term investments) $446 m easily covers August repayment of the $202.5 m 2025 converts (matured 1-Aug-25). Debt stands at $580 m; subsequent to quarter end the company refinanced via a $300 m revolving facility and retired its Term Loan A, modestly improving flexibility. Share repurchases totalled $50 m, bringing treasury shares to 2.79 m.
Strategic moves. February’s $39 m acquisition of GQ Bio adds PCRX-201 gene-therapy platform and created $20.3 m of goodwill. Management also decommissioned a 45-L EXPAREL suite, booking $6.5 m of accelerated depreciation and a $1 m inventory reserve, actions expected to streamline manufacturing from 2H-25.
Six-month view. H1 revenue up 1.4 % to $350 m but essentially break-even (-$0.04 m). Operating cash flow fell to $47 m (vs $102 m) on working-capital build and higher R&D.
FAQ
What is the current stock price of Tela Bio (TELA)?
What is the market cap of Tela Bio (TELA)?
What is TELA Bio, Inc.'s primary focus?
How does TELA Bio address unmet needs in surgery?
What are the key product areas for TELA Bio?
How does TELA Bio generate revenue?
What differentiates TELA Bio's approach from traditional methods?
How does TELA Bio maintain clinical and operational excellence?
